There is no question that obesity is one of the most common healthcare problems plaguing the modern world. According to the National Health and Nutrition Examination Survey (NHANES), 42.4% of Americans suffer from obesity, while 30.7% are on their way to becoming obese. Moreover, approximately 1
The U.S. landscape of biotechnology and pharmaceutical research is marked by clusters of innovation, investment, and scientific output. For 2024, several regions stand out due to their exceptional contributions to the biopharma sectors, from Boston’s academic might to San Diego’s venture capital inf
In a series of unexpected events, a seemingly minor code violation involving a green garden hose led to the discovery and subsequent shutdown of an unlicensed lab in Reedley, California. The facility, operated by Prestige Biotech and Universal Meditech, revealed a dangerous assortment of hazardous
PCI Pharma Services has made a monumental $365 million investment to enhance its capabilities in the assembly and packaging of sophisticated drug-device combination products, particularly those involving injectable formats. This global Contract Development and Manufacturing Organization (CDMO) aims
Europe's rich heritage in pharmaceutical innovation has significantly shaped the global landscape. Yet, recent decades have seen this continent cede its leading position to the U.S. and witness emerging markets like China and India surge ahead. The question now is whether Europe can chart a
BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment
In a significant move within the life sciences industry, Cryoport, Inc. and SK pharmteco have announced a strategic partnership focused on advancing cell and gene therapy. This collaboration aims to integrate logistics and manufacturing services for biotechnology and pharmaceutical companies,
Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both
KBI Biopharma, a prominent contract development and manufacturing organization (CDMO), encountered a critical issue during a GMP (Good Manufacturing Practice) production run. An unexpected pink discoloration appeared in the cell culture media, a crucial component for biologic drug production. The
The clinical research landscape is on the cusp of a transformative shift with the U.S. Food and Drug Administration (FDA) poised to implement a groundbreaking regulation by May 2025. This regulation mandates the use of a single, centralized institutional review board (sIRB) for multisite trials,
